The recent pandemic
caused by SARS-CoV-2 has led the world to a
standstill, causing a medical and economic crisis worldwide. This
crisis has triggered an urgent need to discover a possible treatment
strategy against this novel virus using already-approved drugs. The
main protease (Mpro) of this virus plays a critical role in cleaving
the translated polypeptides that makes it a potential drug target
against COVID-19. Taking advantage of the recently discovered three-dimensional
structure of Mpro, we screened approved drugs from the Drug Bank to
find a possible inhibitor against Mpro using computational methods
and further validating them with biochemical studies. The docking
and molecular dynamics study revealed that DB04983 (denufosol) showed
the best glide docking score, −11.884 kcal/mol, and MM-PBSA
binding free energy, −10.96 kcal/mol. Cobicistat, cangrelor
(previous computational studies in our lab), and denufosol (current
study) were tested for the in vitro inhibitory effects on Mpro. The
IC
50
values of these drugs were ∼6.7 μM, 0.9
mM, and 1.3 mM, respectively, while the values of dissociation constants
calculated using surface plasmon resonance were ∼2.1 μM,
0.7 mM, and 1.4 mM, respectively. We found that cobicistat is the
most efficient inhibitor of Mpro both in silico and in vitro. In conclusion,
cobicistat, which is already an FDA-approved drug being used against
HIV, may serve as a good inhibitor against the main protease of SARS-CoV-2
that, in turn, can help in combating COVID-19, and these results can
also form the basis for the rational structure-based drug design against
COVID-19.